The manufacturer of raloxifene is currently Eli Lilly and Company [1]. Raloxifene is marketed under the brand name Evista [2].
What is Raloxifene Used For?
Raloxifene is a selective estrogen receptor modulator (SERM) used to prevent and treat osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for invasive breast cancer [3].
When Did Raloxifene's Patent Expire?
The original patents for raloxifene have expired, allowing for the production of generic versions [4]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would include specific expiry dates for raloxifene and its related patents [5].
Are There Generic Versions of Raloxifene Available?
Yes, generic versions of raloxifene are available [4]. The availability of generics typically follows the expiry of primary patents.
Who Else Makes Raloxifene?
With patent expiries, other pharmaceutical companies can manufacture and market generic raloxifene. Specific manufacturers of generic raloxifene can vary by region and availability [4].
How Does Raloxifene Work?
Raloxifene works by mimicking the beneficial effects of estrogen on bones while blocking estrogen's effects on breast and uterine tissue [3]. This action helps to reduce bone loss and decrease the risk of fractures in postmenopausal women [3].
What Are the Risks Associated with Raloxifene?
Common side effects of raloxifene include hot flashes, leg cramps, and increased risk of blood clots, such as deep vein thrombosis and pulmonary embolism [3]. Patients should discuss their individual risk factors with a healthcare provider [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drugs/raloxifene
[3] https://www.drugpatentwatch.com/drug/evista
[4] https://www.drugpatentwatch.com/drugs/raloxifene/generics
[5] https://www.drugpatentwatch.com/